Inhibikase Therapeutics Inc (IKT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Inhibikase Therapeutics Inc stock $1.05, price $1.50, that is 30.3% below the price, quality 29 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $0.8100 – $14.58 · fair‑value band $0.6885 – $1.31 · the $1.50 price screens above the $1.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Inhibikase Therapeutics in your weekly email
Every Wednesday you see whether Inhibikase Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Show moreShow less
It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib.
IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance.
Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001.
The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Stock analysis
Inhibikase Therapeutics Inc (IKT) currently trades at $1.50, while our model-based Fair Value estimate is $1.05, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.6885 (bear) to $1.31 (bull), the price of $1.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Inhibikase Therapeutics Inc reported revenue of $0 in FY2025 versus $3.1M in FY2021. Reported net income was −$48.3M in FY2025.
Key figures
Market cap $262M Micro · EPS (TTM) $−0.4300 · Return on equity −52.0% · Return on assets (EBIT) −60.7% (5-year average) · Revenue (TTM) $1 · Free cash flow −$27.8M · Net cash $139M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −30%, IKT screens richer than that median.
Fair Value models
Bear$0.6885Fair Value $1.05Bull$1.31
Price $1.50 · Downside -30.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.8100$1.23$1.5452
All 1 models by family
Asset-Based
NCAV (Graham)$0.8100$1.23$1.5452
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
BuyFrank M. Sands10% owner2,068,965 shares at $1.45$3.0MNov 21, 2025
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+111.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−42.2%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.1%
’16
’17
’18
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.5% (2018) → −7,712.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Inhibikase Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−30.3% · Above median
Profitability
Return on assets−26.6% · Below median
Operating margin (12 months)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Inhibikase Therapeutics Inc (IKT) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.05 versus a price of $1.50, about 30% lower (overvalued).
What is the fair value of IKT?
Our model-based fair value for Inhibikase Therapeutics Inc is $1.05 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.50.
What is the quality score of IKT?
Inhibikase Therapeutics Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Inhibikase Therapeutics Inc (IKT)?
Our model-based price target is the fair value of $1.05 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.6885, optimistic scenario $1.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Inhibikase Therapeutics Inc stock forecast for 2026?
Our models put fair value at $1.05, about 30% lower versus a price of $1.50 (overvalued). Cautious scenario $0.6885, optimistic scenario $1.31. The calculation is refreshed regularly with new filings.
What is the revenue of Inhibikase Therapeutics Inc (IKT)?
Inhibikase Therapeutics Inc reported trailing-twelve-month revenue of about $1 (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Inhibikase Therapeutics Inc (IKT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Inhibikase Therapeutics Inc it is $1.05 per share (as of Nov 8, 2026), against a price of $1.50. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Inhibikase Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, IKT trades above its calculated fair value: price $1.50, fair value $1.05, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IKT?
No. The price is what the market pays today ($1.50); the fair value is what the company's own numbers justify ($1.05). For Inhibikase Therapeutics Inc the two are $0.4545 per share apart. That gap is exactly why we show both numbers side by side.
How much is Inhibikase Therapeutics Inc worth?
The market values Inhibikase Therapeutics Inc at about $262M (market capitalisation, as of Nov 8, 2026). Per share that is $1.50; our models calculate a fair value of $1.05 per share.
What do the bullish and bearish scenarios say about IKT?
Our models span a range for Inhibikase Therapeutics Inc: cautious scenario $0.6885, base $1.05, optimistic $1.31 per share (as of Nov 8, 2026, price $1.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Inhibikase Therapeutics Inc (IKT)?
Balance-sheet figures for Inhibikase Therapeutics Inc (as of Nov 8, 2026): return on equity −52.0%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is IKT from its 52-week high?
Inhibikase Therapeutics Inc trades at $1.50, about 40% below its 52-week high of $2.52 and 6% above the low of $1.41 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.05 is for.
Which stocks are comparable to Inhibikase Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Inhibikase Therapeutics Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $1.50, calculated fair value $1.05 (−30%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IKT calculated?
We run Inhibikase Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.05 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Inhibikase Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Inhibikase Therapeutics Inc (IKT)?
The closing price on Nov 6, 2026 was $1.50. Our model-based fair value is $1.05, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Inhibikase Therapeutics Inc right now?
The price sits above even our optimistic bull case ($1.31). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.6885 to $1.31) leaves room in how you read the outcome.
Key figures of Inhibikase Therapeutics Inc
How large is the market capitalisation of Inhibikase Therapeutics Inc (IKT)?
The market capitalisation of Inhibikase Therapeutics Inc is $262M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Inhibikase Therapeutics Inc (IKT)?
Earnings per share at Inhibikase Therapeutics Inc are $−0.4300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Inhibikase Therapeutics Inc (IKT)?
The return on equity (ROE) of Inhibikase Therapeutics Inc is −52.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Inhibikase Therapeutics Inc (IKT)?
On an EBIT basis the return on assets of Inhibikase Therapeutics Inc is −60.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Inhibikase Therapeutics Inc (IKT) generate?
The free cash flow of Inhibikase Therapeutics Inc is −$27.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Inhibikase Therapeutics Inc (IKT) hold?
Inhibikase Therapeutics Inc holds more cash than debt, $139M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Inhibikase Therapeutics Inc in the live analysis
One click puts Inhibikase Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
